ACT—The high-priced FRX deal could be what finally ends the illusion of robust growth from Actavis’s serial roll-ups. This business model almost always ends badly, but it can support a lofty valuation for a pretty long time until investors figure it out.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.